Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to twelve new employees on November 1, 2024. The awards consist of non-qualified share options to purchase 56,700 ordinary shares under the company's 2024 Inducement Plan. The options have an exercise price of $23.44 per share, based on the closing price on October 31, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato che il suo Comitato per la Compensation ha concesso premi di indotto a dodici nuovi dipendenti il 1° novembre 2024. I premi consistono in opzioni su azioni non qualificate per l'acquisto di 56.700 azioni ordinarie nell'ambito del Piano di Induzione 2024 dell'azienda. Le opzioni hanno un prezzo di esercizio di $23,44 per azione, basato sul prezzo di chiusura del 31 ottobre 2024. Le opzioni matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente per 36 mesi, previa continuazione del rapporto di lavoro.
Bicycle Therapeutics (NASDAQ: BCYC) anunció que su Comité de Compensación otorgó premios de inducción a doce nuevos empleados el 1 de noviembre de 2024. Los premios consisten en opciones de acciones no calificadas para comprar 56,700 acciones ordinarias bajo el Plan de Inducción 2024 de la compañía. Las opciones tienen un precio de ejercicio de $23.44 por acción, basado en el precio de cierre del 31 de octubre de 2024. Las opciones se otorgarán durante cuatro años, con un 25% otorgado después de un año y el resto otorgado mensualmente durante 36 meses, sujeto a la continuidad del empleo.
Bicycle Therapeutics (NASDAQ: BCYC)는 2024년 11월 1일에 보상 위원회가 12명의 신규 직원에게 유인 상금을 부여했다고 발표했습니다. 이 상금은 회사의 2024 유인 계획에 따라 56,700주를 구매할 수 있는 비공식 주식 옵션으로 구성되어 있습니다. 옵션은 2024년 10월 31일 기준 종가를 기반으로 $23.44의 행사 가격을 가지고 있습니다. 옵션은 4년 동안 분산되어 부여되며, 1년 후 25%가 부여되고 나머지는 36개월 동안 매월 부여되며, 지속적인 근무 조건이 충족되어야 합니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé que son comité de rémunération a accordé des awards d'incitation à douze nouveaux employés le 1er novembre 2024. Ces prix consistent en des options d'achat d'actions non qualifiées pour l'achat de 56 700 actions ordinaires dans le cadre du Plan d'incitation 2024 de l'entreprise. Les options ont un prix d'exercice de 23,44 $ par action, basé sur le prix de clôture du 31 octobre 2024. Les options acquièrent des droits sur quatre ans, avec 25 % acquérant des droits après un an et le reste acquérant des droits mensuellement pendant 36 mois, sous réserve de maintien de l'emploi.
Bicycle Therapeutics (NASDAQ: BCYC) gab bekannt, dass sein Vergütungsausschuss am 1. November 2024 Induktionsprämien an zwölf neue Mitarbeiter vergeben hat. Die Prämien bestehen aus nicht-qualified Optionsscheinen zum Kauf von 56.700 Stammaktien im Rahmen des Induktionsplans 2024 des Unternehmens. Die Optionen haben einen Ausübungspreis von $23,44 pro Aktie, basierend auf dem Schlusskurs vom 31. Oktober 2024. Die Optionen werden über vier Jahre verteilt, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate fällig werden, vorbehaltlich eines fortlaufenden Beschäftigungsverhältnisses.
- Addition of twelve new employees indicating company growth
- Implementation of employee retention strategy through stock options
- Potential shareholder dilution from 56,700 new share options
Each option has an exercise price equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101813346/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
How many shares were granted in Bicycle Therapeutics (BCYC) November 2024 inducement awards?
What is the exercise price for BCYC's November 2024 inducement stock options?